INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 431m ago
HOUSE PTR30m ago
SEC 13F30m ago
ROBINHOOD CHAIN30m ago
Public company

AgomAb Therapeutics NV

AGMBCIK 0002020932

EDGAR filingsOpen in network
Price$7.64
1 year-47.9%
Disclosed transactions10
Buys / sells10 / 0
Max Insider Score49
Connections with evidence4

AGMB · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
29
ER
Epstein David RDirector
AGMBAgomAb Therapeutics NV
Open-market purchase
BUY$35K
5,000 sh
Nov 5, 2026Nov 6, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Epstein David RDirector · Oct 22, 2026
  • ← Insider ofevidence
    Knotnerus Tim JasperDirector, Chief Executive Officer · Oct 7, 2026
  • ← Insider ofevidence
    Kemula Pierre Thadee VictorChief Financial Officer · Oct 7, 2026
traded Nov 5, 2026
+1d
SEC FORM 4

Evidence

33
ER
Epstein David RDirector
AGMBAgomAb Therapeutics NV
Open-market purchase
BUY$34K
5,000 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

29
ER
Epstein David RDirector
AGMBAgomAb Therapeutics NV
Open-market purchase
BUY$35K
5,000 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC FORM 4

Evidence

37
ER
Epstein David RDirector
AGMBAgomAb Therapeutics NV
Open-market purchase
BUY$44K
5,000 sh
Oct 21, 2026Oct 22, 2026
traded Oct 21, 2026
+1dSEC FORM 4

Evidence

37
ER
Epstein David RDirector
AGMBAgomAb Therapeutics NV
Open-market purchase
BUY$45K
5,000 sh
Oct 21, 2026Oct 22, 2026
traded Oct 21, 2026
+1dSEC FORM 4

Evidence

49
KJ
Knotnerus Tim JasperDirector, Chief Executive Officer
AGMBAgomAb Therapeutics NV
Open-market purchase
BUY$51K
6,000 sh
Oct 5, 2026Oct 7, 2026
traded Oct 5, 2026
+2dSEC FORM 4

Evidence

38
KJ
Knotnerus Tim JasperDirector, Chief Executive Officer
AGMBAgomAb Therapeutics NV
Open-market purchase
BUY$44K
5,000 sh
Oct 6, 2026Oct 7, 2026
traded Oct 6, 2026
+1dSEC FORM 4

Evidence

46
KV
Kemula Pierre Thadee VictorChief Financial Officer
AGMBAgomAb Therapeutics NV
Open-market purchase
BUY$26K
3,000 sh
Oct 6, 2026Oct 7, 2026
traded Oct 6, 2026
+1dSEC FORM 4

Evidence

42
KV
Kemula Pierre Thadee VictorChief Financial Officer
AGMBAgomAb Therapeutics NV
Open-market purchase
BUY$17K
2,000 sh
Oct 6, 2026Oct 7, 2026
traded Oct 6, 2026
+1dSEC FORM 4

Evidence

46
KV
Kemula Pierre Thadee VictorChief Financial Officer
AGMBAgomAb Therapeutics NV
Open-market purchase
BUY$43K
5,000 sh
Oct 6, 2026Oct 7, 2026
traded Oct 6, 2026
+1dSEC FORM 4

Evidence